Zenith Drugs Ltd. Hits Upper Circuit on NSE, 23 September 2026

On 23 September 2026, Zenith Drugs Ltd. (ZENITHDRUG) hit the upper circuit on NSE at Rs 49.5, a 19.71% positive move from the previous close of Rs 41.35. The company's market cap stood at Rs 70.91 crore. The upper circuit price for the session was Rs 49.6.

The move was driven by buying interest against the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Key Takeaways

• Zenith Drugs Ltd. (ZENITHDRUG) hit the upper circuit on NSE at Rs 49.6 on 23 September 2026.
• The session move was +19.71% against a previous close of Rs 41.35.
• Market capitalisation stood at Rs 70.91 crore with a PE ratio of 17.99.
• No official company announcement or verified catalyst was confirmed at the time of writing.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric	Value
Stock	Zenith Drugs Ltd.
Current Price / LTP	Rs 49.5
Day Move	19.71%
Previous Close	Rs 41.35
Day Open	Rs 41.5
Day High	Rs 49.5
Day Low	Rs 41
Upper Circuit Price	Rs 49.6
Upper Circuit Limit	Rs 49.6
Market Cap	Rs 70.91 crore
Selected Exchange	NSE
PE Ratio	17.99

All figures above are as of 23 September 2026, sourced from Univest market data for the NSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Zenith Drugs Ltd. opened at Rs 41.5 on NSE, compared with a previous close of Rs 41.35. During the session, the stock traded between Rs 41 and Rs 49.5 before touching the upper circuit price of Rs 49.6.

The absolute day change was Rs 8.15, while the percentage move was 19.71%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range, and previous-close values can differ across exchanges. This article uses NSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 49.6, which is the level the price reached.

Why Zenith Drugs Ltd. Hit Upper Circuit

Zenith Drugs Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 49.6.

What the Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Zenith Drugs Ltd., the captured upper circuit price was Rs 49.6 on 23 September 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Zenith Drugs Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Zenith Drugs Ltd., PE ratio was 17.99, PB ratio was 1.02, book value was Rs 40.46, EPS was 2.3, ROE was 10.88%, ROCE was 12.96%, dividend yield was 0% and debt-to-assets ratio was 0.7, on a market cap of Rs 70.91 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

A PB ratio above 1 means the market price was above the reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Zenith Drugs Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company	Market Cap	PE	PB	ROE
Hikal Ltd.	Rs 2825.44 crore	-	2.36	16.04%
Dishman Carbogen Amcis Ltd.	Rs 2670.02 crore	164.84	0.4	0.32%
Sakar Healthcare Ltd.	Rs 2577.54 crore	73.25	7.9	11.88%
Indoco Remedies Ltd.	Rs 2370.36 crore	417.01	2.35	18.5%
Windlas Biotech Ltd.	Rs 2331.58 crore	34.23	4.42	12.87%

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Several of these peers are far larger by market capitalisation than Zenith Drugs Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Zenith Drugs Ltd.'s PE ratio was 17.99, compared with an available peer/sector PE average of 137.87, calculated from the 4 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical and Ownership Snapshot

The technical snapshot adds context: RSI was 33.65.

Worth flagging: the RSI reading sits on the opposite side of neutral to the day move. Indicator values in the dataset can lag the live session, so they should be checked against a live chart before being relied on.

Shareholding details were not available in the latest market dataset, so no conclusion is drawn about promoter, institutional, or public-shareholder activity.

What Readers Should Know

The main confirmed fact is that Zenith Drugs Ltd. hit the upper circuit on NSE at Rs 49.6 on 23 September 2026, with a 19.71% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Zenith Drugs Ltd. hit upper circuit on 23 September 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was ZENITHDRUG share price on 23 September 2026?

The last traded price used in this article was Rs 49.5 on NSE.

What was the upper circuit price for ZENITHDRUG?

The upper circuit price was Rs 49.6. The stated exchange upper circuit limit was Rs 49.6. The event numbers in this article are aligned to NSE.

What is Zenith Drugs Ltd.'s market cap and PE ratio?

Zenith Drugs Ltd.'s market cap was Rs 70.91 crore. PE ratio was 17.99.

Which exchange and data source were used?

The selected exchange was NSE. The article uses Univest market data available at the time of generation, captured on 23 September 2026.

Does hitting an upper circuit mean Zenith Drugs Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Zenith Drugs Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Zenith Drugs Ltd. the stated limit was Rs 49.6. For this session, Zenith Drugs Ltd. moved 19.71%.

Footer Disclosure

This article is for informational purposes only and does not constitute investment advice. Research services are provided by Uniapps Investment Adviser Pvt. Ltd., a wholly owned subsidiary of Univest, SEBI RIA registration number INA000017639.